MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Frontiers in Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

842 results · 1 filter active ·
Results by year
20112025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
842 works in the cohort · of 4,299,418page 9 of 17

Labels cover 4 of 842 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 842 of 842 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

fundno affunlabeled
Editorial: Targeted Therapies for Glioblastoma: A Critical Appraisal
Shiv K. Gupta, Sani H. Kizilbash, David J. Daniels, Jann N. Sarkaria
2019· editorial· en· Frontiers in Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaresearch+metaepi_narrow+research_integrityconsensus · none
12
citations
affunlabeled
Editorial: Hallmark of cancer: Resisting cell death
Yichao Zhu, Risheng Yang, Jacqueline H. Law, Muhammad Zafar Irshad Khan, Kenneth W. Yip, Qiang Sun
2022· editorial· en· Frontiers in Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrow+research_integrityconsensus · none
10
citations
affunlabeled
Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the European Lung Cancer Working Party
Thierry Berghmans, Lieveke Ameye, Jean‐Jacques Lafitte, Benoît Colinet, Alexis B. Cortot, Ingrid CsToth +12 more
2015· article· en· Frontiers in Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
10
citations
affunlabeled
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors
Toshio Shimizu, John D. Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D. Miller, Steven Kao +10 more
2024· article· en· Frontiers in Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
10
citations
← previousnext →

How this was built: Screen · Findings · About